Skip to content

A Phase II, single-blind, randomized, controlled study to evaluate the immunogenicity and safety of a measles, mumps, rubella, varicella vaccine compared with ProQuad, administered in healthy children 4 to 6 years of age (GSK 217715 [MMRVNS 20-001])

Nicola Klein | Industry Ongoing

Explore all studies

Back To Top